Association Between Somatic PIK3CA Mutations and Ancestry in 1 South Asia: Prognostic Insights From a Sri Lankan Breast 2 **Cancer Study** 3 Tharini Ruwinya Cabraal<sup>1\*</sup>, Iranthi Kumarasinghe<sup>2</sup>¶, Ranga Perera<sup>2</sup>¶, Jayantha Balawardane<sup>2</sup>¶, 4 5 Sameera Viswakula<sup>3</sup>¶, Nandika Perera<sup>4</sup>¶, Gayani Harendra Galhena<sup>1\*</sup> 6 1. Centre for Immunology and Molecular Biology, Department of Zoology & 7 Environmental Sciences, Faculty of Science, University of Colombo, Colombo, Sri 8 Lanka 9 2. University Hospital, General Sir John Kotelawala Defence University, Colombo, Sri 10 Lanka 11 3. Department of Statistics, Faculty of Science, University of Colombo, Colombo, Sri 12 Lanka 4. Genetech Molecular Diagnostics, Colombo, Sri Lanka 13 14 15 \*Corresponding Authors: 16 Prof. Gavani Harendra Galhena 17 Email: gayani@zoology.cmb.ac.lk (GHG) 18 ORCID: https://orcid.org/0000-0002-1617-6612 19 20 Tharini Ruwinya Cabraal 21 Email: tharinicabraal@gmail.com 22 ORCID: https://orcid.org/0009-0003-8943-0110 23 24 ¶ These authors contributed equally to this work.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

# Abstract (299 words)

# **Background**

25

26

32

- 27 The PIK3CA oncogene is one of the most mutated oncogenes in breast cancer, with ancestry-
- 28 linked variations reported globally. The study aimed to discern the prevalence and prognostic
- 29 role of PIK3CA mutations in Sri Lankan breast cancer patients for the first time, focusing on
- 30 the correlation between somatic mutations and patient ancestry in an exclusively South Asian
- 31 cohort of breast cancers.

## **Materials & Methods**

- A qPCR-based genetic analysis was performed on DNA from formalin-fixed, paraffin-33
- 34 embedded (FFPE) tissue samples of 63 clinically diagnosed, female, Sri Lankan breast cancer
- 35 patients using the QClamp® PIK3CA Mutation Detection Test for the hotspot mutations of
- 36 PIK3CA (i.e., H1047R, E545K, E542K) followed by a statistical analysis. Patient samples
- 37 and clinical data were fully anonymized, with no identifying information available to authors
- 38 at any point of the study.

### **Results** 39

- 40 Somatic missense PIK3CA mutations H1047R and E542K, were detected in 17.46% of the
- 41 cohort. E545K mutation was not detected. The observed mutations were associated with an
- 42 increased risk of lymph node (LN) metastasis (p=0.036, OR 9.60) and reduced recurrence-
- 43 free survival (RFS) (p<0.001, HR 26.19). In addition, LN metastasis (p=0.026, HR 123.94)
- 44 and a high Ki67 index (p=0.029, HR 79.69) were individually associated with reduced RFS.
- All three factors above- presence of a PIK3CA mutation, LN metastasis and a high Ki67 45
- 46 index- in combination, were also associated with reduced RFS (p<0.001). Further analysis
- 47 revealed a significant association between patient ancestry and PIK3CA mutation status
- (p=0.028).48

49

## **Conclusion**

- Despite being a pilot study, the findings suggest that PIK3CA may serve as a potential 50
- 51 prognostic biomarker in Sri Lankan breast cancer patients, with ancestry-linked variations
- 52 potentially influencing metastatic outcomes. These results bring out the importance of
- 53 integrating PI3K inhibitors into the therapeutic management of breast cancers in Sri Lanka
- 54 after validating these findings in a functional study using a larger cohort.

# Introduction

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

Breast cancer is the most commonly diagnosed cancer in women worldwide [1]. Asian women, particularly those in developing countries, often have a poorer prognosis for breast cancer, with higher cancer grades and stages as well as an earlier onset of the disease [2]. Breast cancer has distinct molecular subtypes that are categorized based on the immunohistochemical (IHC) expression of steroid hormone receptors (SHR), including estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2/ERBB2 or HER2/neu). These subtypes are Luminal A, Luminal B, HER2positive (HER2+), and triple-negative breast cancer (TNBC) [1]. More than 85% of breast cancers are sporadic, primarily caused by somatic mutations [3]. These mutations in oncogenes (OGs) and tumor suppressor genes (TSGs) often initiate tumorigenesis [4]. Breast cancer tumorigenesis has been linked to mutations in several cell signaling pathways crucial for normal development such as the PI3K/AKT/mTOR pathway, commonly referred to as the PI3K pathway. Genetic hyperactivation of this pathway is one of the most common driver mechanisms in breast cancer, often through alterations to its components like p110a (encoded by the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha gene/PIK3CA; NCBI Gene ID 5290), p110β, and p85α [1,5,6]. Approximately 30% of the mechanisms that over-activate PI3K signaling are due to somatic mutations in the PIK3CA oncogene [5], making it the most commonly mutated oncogene in breast cancer [6-8]. While PIK3CA mutations can occur across the p110α subunit, about 80% are caused by the three hotspot mutations clustered in two domains of p110α: E545K and E542K in the helical domain encoded by exon 9, and H1047R in the kinase domain encoded

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

94

95

96

97

98

99

100

by exon 20. Among these, H1047R is the most frequently detected *PIK3CA* mutation, while E542K is the least prevalent [9]. Studies have shown that between 10 to 45% of all human breast cancers harbor *PIK3CA* driver mutations, with the exact percentage varying based on the studied population and ancestry [5-10]. Activating mutations of PIK3CA are reported in nearly 42% of SHR+/HER2-, 31% of HER2+ and 16% of TNBC tumors [5]. Importantly, the presence of *PIK3CA* mutations has been associated with poorer prognostic outcomes, especially in ER+ cases [11]. Numerous studies illustrate that PIK3CA mutations are linked with resistance to various therapies, including endocrine therapy, chemotherapy, radiotherapy, anti-HER2 therapy and immunotherapy. This resistance negatively affects all available treatment modalities for all breast cancer subtypes, with more pronounced effects in advanced and metastatic cases [5,7-10,12]. These mutations also promote cell division and inhibit apoptosis in TNBC cells, leading to resistance to their primary treatment option: chemotherapy [12]. In addition to their role in treatment resistance, accumulating evidence suggests a strong association between PIK3CA mutations and tumor recurrence, poor relapse/recurrence-free survival (RFS), and/or overall survival (OS), particularly in postoperative Asian patients with metastatic SHR+/HER2- breast cancers [9,11,13-15]. Despite extensive research, the overall relationship between PIK3CA mutations and the clinicopathological profile of breast cancer patients remains controversial, with conflicting findings across various patient populations, such as observed associations of PIK3CA mutations with longer RFS and/or OS [16,17]. Recent advances in genomic studies have provided significant insights into the relationship between genetic ancestry and somatic mutations across cancer types via changes in the germline [18-22]. In particular, the *PIK3CA* oncogene is reported as one of the top two genes

102

103

104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

observed in breast cancers, whose somatic mutations have shown significant ancestry-linked differences in several global studies predominantly involving patients from European and African ancestries [19-21]. However, Asian populations, particularly those of South Asian descent, remain highly underrepresented in these studies, limiting a comprehensive understanding of ancestry-driven somatic mutations in the region [22]. Sri Lanka is a unique island nation in the Indian Ocean with a rich tapestry of ethnic diversity. Over 70% of the population is composed of Sinhalese, descendants of Indo-Aryan ancestry, found exclusively in Sri Lanka [23]. Other major ethnic groups include Tamils and Moors, who trace their roots to Dravidian ancestry, and Burghers, descendants of European colonists in Sri Lanka, who also share Indo-Aryan ancestry [23,24]. This distinct combination of Indo-Aryan and Dravidian ancestries, together with its centralized geographical location, particularly during the maritime silk route, makes Sri Lanka a melting pot of genetic diversity. Breast cancer is the most frequently diagnosed cancer among Sri Lankan women [25]. As a developing, lower-middle income island nation in the Indian Ocean, Sri Lanka has limited research on breast cancer trends and genetic markers, despite a significant rise in incidence and mortality rates over time [26,25]. To the best of our knowledge, no studies have been conducted on the prevalence and prognostic outcomes of PIK3CA mutations and their correlations with ancestry in breast cancer patients of Sri Lanka. Given the mutational spectrum of PIK3CA and its impact on the clinicopathological profile and prognosis of breast cancer, which varies significantly depending on the population and their ancestry, it is important to elucidate the current status of Sri Lankan breast cancer patients in this context – an area that remains largely unexplored. This study was therefore designed to achieve the overarching aim of cataloguing hotspot mutations in the *PIK3CA* oncogene within a cross-section of Sri Lankan breast cancer patients

that includes all different ancestral groups. Using DNA extracted from tumor tissues obtained at the point of diagnosis, we aimed to correlate the detected mutations with specific clinicopathological characteristics and ultimately assess the prognostic potential of PIK3CA mutations using RFS as a key metric. Given that the Sinhalese population is found nowhere else in the world (except for few migrant individuals), results from this study offer a rare opportunity to explore how ancestral genetic makeup in an island nation intersects with somatic mutations, such as those in the *PIK3CA* oncogene. This study managed to successfully catalog PIK3CA mutations in our cohort of Sri Lankan breast cancer patients and deduced their impacts on disease prognosis while addressing the critical gap on the implications of ancestry on somatic mutations in a purely South Asian cohort of breast cancer patients, for the first time.

# Materials and methods

## **Patient samples**

125

126

127

128

129

130

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

Ethical approval for the analysis of an existing set of formalin-fixed paraffin-embedded (FFPE) breast tumor biopsy samples and fully anonymized medical records of the relevant patients was obtained from the Ethics Review Committee of the Institute of Biology, Sri Lanka (ERC IOBSL 303 07 2023, S1 Fig). This retrospective study was conducted in compliance with the REMARK (Reporting Recommendations for Tumor Marker Prognostic Studies) and ICMJE (International Committee of Medical Journal Editors) guidelines. The fully anonymized database of breast cancer patient records from the Diagnostics Laboratory at the University Hospital of General Sir John Kotelawala Defense University was accessed on the 27th of August 2023. All patient data were fully anonymized, ensuring no patient identifiers were available to the authors at any stage of the research. Using this database,

medical records of breast cancer patients treated at the University Hospital of General Sir John

Kotelawala Defense University from 2019 to 2023, who met the inclusion criteria (Fig 1) were selected for the study. The corresponding FFPE blocks were retrieved from the hospital's diagnostics laboratory and stored at room temperature until further Clinicopathological data and follow-up information of these patients ranging from 1 to 5 years post-diagnosis were collected from the hospital database. To ensure patient anonymity, medical and follow-up data of individual patients were recorded, and the samples were identified exclusively using identification numbers assigned to each sample for the purpose of research. Therefore, as authors did not have access to information that could identify individual participants during or after data collection, total anonymity of patient identity was maintained throughout the study.

## Fig 1. Flowchart of patient enrollment, inclusion criteria, and study workflow

## DNA extraction and hotspot mutation assay

148

149

150

151

152

153

154

155

156

157

158

159

160

161

162

163

164

165

166

167

168

169

170

Genomic DNA was extracted from FFPE samples using the QIAamp DNA FFPE Tissue Kit according to the manufacturer's instructions (Cat. No. 56404; Qiagen, Hilden, Germany) and assessed for quality and quantity using the Thermo Scientific<sup>TM</sup> NanoDrop<sup>TM</sup> One Spectrophotometer. The three hotspot mutations of the *PIK3CA* oncogene- H1047R, E545K, and E542K- were genotyped in 63 of the selected samples using the QClamp® PIK3CA Mutation Detection Test Kit (Cat. No. DC-10-1072R; DiaCarta, CA 94588, USA), which utilized a Xeno-nucleic acid (XNA)-based mutation-specific quantitative real-time polymerase chain reaction (qPCR) method.

# **Endpoint and statistical analysis**

The prevalence of PIK3CA mutations in the study cohort and their associations with clinicopathological features were determined using the  $\chi^2$  test. Fisher's exact test was

172

173

174

175

176

177

178

179

180

181

182

183

184

185

186

187

188

189

190

191

192

193

employed for dichotomous features. To enhance the statistical validity and minimize the risk of type I errors, patients were grouped according to significant, widely accepted clinicopathological cutoffs in oncology based on the sample size available for each category (S1 Table). In the analysis of ancestry, patients grouped into Indo-Arvan ancestry (Sinhalese & Burghers) were compared to those of Dravidian ancestry (Tamils & Moors). Depending on data normality, either a t-test or Mann-Whitney Test was performed to compare the mean or median of populations for the relevant variables. For specific variables showing significant associations, binary logistic regression was used to obtain the odds ratio (OR) and the 95% confidence interval (CI). This binary logistic regression model assumed that there were no significant multicollinearity issues, and all independent variables were linearly related to the log-odds of the dependent variable. All patients underwent routine clinical examinations at the hospital every 3-6 months, and the clinicopathological variables analyzed were those recorded at the initial diagnosis. Since all patients with survival data (n=42) were alive at the last follow-up, RFS was used as the survival metric instead of OS, and was defined as the time from the date of curative surgery to the clinical diagnosis of recurrence. Events considered in RFS included distant and local invasive recurrence. Patients without survival data were excluded from the survival analysis. The median follow-up time after diagnosis was 37.00 months (0.00–81.19). The Kaplan-Meier method was used to plot RFS, while the Mantel-Cox log-rank test was applied to compare different subgroups of the variables. Significant parameters identified by the log-rank test (p<0.05) were further analyzed using a univariate Cox proportional hazard regression model. A multivariate model was finally used to analyze the combined effect of all significant associations on RFS. However, for parameters which could not generate a

statistically robust Cox proportional hazard regression model due to limited data on survival, only the p-value was reported.

Samples with missing data for the variable of interest were excluded from specific analyses. All statistical tests were two-sided and a p-value below 0.05 was considered statistically significant. Analyses were performed using SPSS 25 (Released 2017. IBM SPSS Statistics for Windows, Version 25.0. Armonk, NY: IBM Corp.) and R (version 4.0.2, R Foundation for Statistical Computing, Vienna, Austria).

# **Results**

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

212

# Analysis of the clinicopathological features and ethnicity

The studied cohort consisted of 66 patients clinically diagnosed with breast cancer between 2019 and 2023. The median age at the time of diagnosis was 58.00 years (S2 Fig).

Table 1 presents several key characteristics of the cohort. Accordingly, IHC analysis revealed that over 80% of the tumors were SHR-positive HER2-negative luminal subtypes, with luminal A and B subtypes occurring in equal proportions. Over 95% of the cohort comprised of Sinhalese patients while the remaining 5% included two Tamil patients, one Moor, and one Burgher patient. This represents only a rough approximation of the actual ethnic distribution in Sri Lanka, where approximately 72% of the population are Sinhalese [23].

Table 1. Clinicopathological and population characteristics of the cohort

Age at diagnosis	No. of patients	%
<35	0	0.00
36-45	5	7.58
46-55	20	30.30
56-65	19	28.79
66-75	15	22.73
76-85	6	9.09
>85	1	1.52
Side	No. of patients	%

Table 1 continued

L/S	30	45.45
R/S	36	54.55
Site of the tumor	No. of patients	%
Upper outer quadrant	2	3.03
Upper inner quadrant	14	21.21
Lower inner quadrant	0	0.0
Lower outer quadrant	3	4.55
Central	5	7.58
Clock Positions	22	33.33
Two quadrants	2	3.03
Unknown	18	27.27
Histological type	No. of patients	%
IBC-NST	57	86.36
Invasive mucinous carcinoma	4	6.06
Histological type	No. of patients	%
Invasive lobular carcinoma	2	3.03
Invasive papillary carcinoma	<u>-</u> 1	1.52
Invasive tubular carcinoma	1	1.52
DCIS	1	1.52
Tumor grade/ differentiation	No. of patients	%
Grade 1/ well-differentiated	22	33.34
Grade 2/ moderately	37	56.06
differentiated	5,	20.00
Grade 3/ poorly differentiated	5	7.57
Unknown	2	3.03
Tumor size	No. of patients	%
≤2 cm	12	18.18
>2 cm	37	56.06
Unknown	17	25.76
Pathological tumor stage	No. of patients	%
Tis	1	1.52
pT1	10	15.15
pT2	31	46.97
pT3	6	9.09
Unknown	18	27.27
Pathological nodal stage	No. of patients	%
pN0	29	43.94
pN1	13	19.70
Pathological nodal stage	No. of patients	%
pN2	6	9.09
pN3	2	3.03
Unknown	16	24.24
Lymph node metastasis	No. of patients	%
Positive	21	31.82
Negative	29	43.94
Unknown	16	24.24
ER status	No. of patients	%
	•	

213

214

TD 11 1		1
Table I	continued	٦
I auto I	Commuce	J

ER+	60	90.91
ER-	6	9.09
PR status	No. of patients	%
PR+	46	69.70
PR-	20	30.30
SHR status	No. of patients	%
SHR+	60	90.91
SHR-	6	9.09
HER2 status	No. of patients	%
HER2+	6	9.09
HER2-	59	89.39
Unknown	1	1.52
Receptor based subtype	No. of patients	%
SHR+/HER2-	55	83.34
SHR+/HER2+	4	6.06
Receptor based subtype	No. of patients	%
SHR-/HER2+	2	3.03
SHR-/HER2-	4	6.06
Unknown	1	1.51
Ki67 Proliferation index	No. of patients	%
<20% (low)	30	45.45
≥20% (high)	28	42.42
Unknown	8	12.12
IHC-based molecular	No. of patients	%
subtype		
Luminal A	24	36.36
Luminal B	24	36.36
Luminal (undetermined for	7	10.60
A/B as Ki67 data unavailable)		
HER2 enriched	6	9.09
TNBC	4	6.06
HER2 unknown	1	1.51
Ethnicity	No. of patients	%
Sinhalese	63	95.45
Tamil	1	1.51
Moor	1	1.51
Burgher	1_	1.51
Ancestry	No. of patients	0/0
Indo-Aryan	64	96.96
Dravidian	2	3.03
	******	

DCIS: ductal carcinoma in-situ, ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, IBC-NST: invasive breast carcinoma of no special type, IHC:immunohistochemical, L/S: left side, pN: pathological nodal stage, PR: progesterone receptor, pT: pathological tumor stage, R/S: Right side, SHR: steroid hormone receptor, Tis: carcinoma in-situ stage, TNBC: triple-negative breast cancer

"Unknown" - samples with data unavailable for the parameter of interest

215

# Prevalence of PIK3CA mutations in the cohort

Missense mutations in the *PIK3CA* oncogene were detected in 17.46% (n=11) of the cohort. The mutations observed included H1047R (c.3140A>G) in 81.81% (n=9) and E542K (c.1624G>A) in 18.18% (n=2) of the mutated samples. Notably, both H1047R and E542K mutations were detected in one sample (co-mutation prevalence: 9.09% of the mutated and 1.58% of the total samples). No E545K mutations (c.1633G>A) were detected in the cohort.

# Association of PIK3CA mutations with clinicopathological

## parameters and ancestry

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

All PIK3CA mutations identified were found in SHR+/HER2- luminal tumors (Table 2). Importantly, a significant association was observed between PIK3CA mutational status and lymph node (LN) metastasis, with patients harboring a *PIK3CA* mutation exhibiting 9.60 times higher odds of LN metastasis compared to those without a PIK3CA mutation (p=0.036, OR 9.60, 95% CI 1.05-87.78). Notably, a significant association was observed between the ancestry of the patients and the presence of a PIK3CA mutation (p=0.028). Other parameters showed no significant association with the mutational status.

Table 2. PIK3CA mutational status and Ki67 proliferative index in selected clinicopathological and ancestral groups

Parameter	Mutations absent (n)	PIK3CA Mutated (n)	Total (n)	p-value
All	52	11	63	
Age at diagnosis				
≤50 years	14	2	16	
> 50 years	38	9	47	0.714
Histological type				
IBC-NST	45	10	55	
Other	7	1	8	1.000

Table 2 continued

		Table 2 continued		
Tumor grade/ differentiation				
G1/ well-	17	4	21	
differentiated				
G2 or G3/ moderately	33	7	40	1.000
or poorly				
differentiated				
Tumor size				
$\leq 2 \text{ cm}$	9	2	11	
> 2 cm	30	5	35	1.000
Mean (cm) (95% CI)	3.5 (2.8-4.2)	3.2 (1.7-4.7)		
Median (cm) (Range)	3.2 (0.7-	3 (1.1-6.0)		0.994
	12.0)			
Pathological tumor				
stage				
Early stage	32	6	38	
(pT1/pT2)				
Late stage (pT3/pT4)	6	1	7	1.000
Lymph node				
Metastasis				
Negative	24	1	25	
Positive	15	6	21	*0.036
ER status				
ER+	47	11	58	
ER-	5	0	5	0.576
PR status				
PR+	37	7	44	
PR-	15	4	19	0.721
SHR status				
SHR+	47	11	58	
SHR-	5	0	5	0.576
HER2 status				
HER2+	6		6	
HER2-	45	11	56	0.580
Receptor based				
subtype				
SHR+/HER2-	42	11	53	
Other	10	0	10	0.187
Ki67 Proliferation				
index				
<20%	23	5	28	
≥20%	22	5	27	1.000
IHC-based				
molecular subtype				
Luminal	42	11	53	
HER2/TNBC	9	0	9	0.341
Ancestry		<u> </u>		
Indo-Aryan	52	9	61	
indo in yun	32	,	01	

Table 2 continued

Dansidian	0	2	2	*n n20
Dravidian	0	2	2	*0.028
Parameter	Ki67	Ki67 ≥ 20%	Total	p-value
	< 20% (Low)	≥ 20 % (High)		
All	30	28	58	
Age at diagnosis	30			
≤50 years	7	7	14	
>50 years	23	21	44	1.000
Histological type				1.000
IBC-NST	23	27	50	
Other	7	1	8	0.053
Tumor grade/	·			
differentiation				
G1/ well-	14	5		
differentiated				
G2 or G3/	15	23	38	<b>▲</b> 0.024
moderately or				
poorly				
differentiated				
Tumor size				
≤ 2 cm	5	5	10	
> 2 cm	20	12	32	0.714
Mean (cm) (95%	3.3 (2.5-4.2)	3.4 (2.3-		
CI)	,	4.5)		
Median (cm)	3.0 (1.2-12.0)	3.3 (0.7-		0.884
(Range)		9.3)		
Pathological				
tumor stage				
Early stage	21	14	35	
(pT1/pT2)				
Late stage	2	3	5	0.634
(pT3/pT4)				
Lymph node				
metastasis				
Negative	17	9	26	
Positive	8	8	16	0.353
ER status				
ER+	27	26	53	
ER-	3	2	5	1.000
PR status				
PR+	23	18	41	
PR-	7	10	17	0.390
SHR status				
SHR+	27	26	53	
SHR-	3	2	5	1.000
HER2 status				
HER2+	3	3	6	

TD 1	1	_				1
Tal	11e	· '	COL	ntı	nn	ed

HER2-	26	25	51	1.000
Receptor based				
subtype				
SHR+/HER2-	24	24	48	
Other	6	4	10	0.732
IHC-based				
molecular subtype				
Luminal	24	24	48	
HER2/TNBC	5	4	9	1.000

<sup>\*:</sup> association is significant at 5% level, OR 9.600, 95% CI 1.050-87.784

CI: confidence interval, ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, IBC-NST: invasive breast carcinoma of no special type, IHC: immunohistochemical, LN: Lymph Node, OR: odds ratio, PR: progesterone receptor, pT: pathological tumor stage, SHR: steroid hormone receptor, TNBC: triple-negative breast cancer

# Associations among other clinical and histopathological

### parameters

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

Table 2 also outlines the associations between the Ki67 proliferation index and other clinicopathological features. A significant association was identified between Ki67 status and tumor grade, with higher Ki67 proliferative indices being linked to a 4.29 times higher likelihood of developing moderately or poorly differentiated breast cancers of higher tumor grades, compared to those with proliferative indices < 20% (p=0.024, OR 4.29, 95% CI 1.28-14.41).

No statistically significant associations were observed between LN metastasis or patient age group and other clinicopathological parameters (S2 Table).

# Impact of *PIK3CA* mutational status on RFS

Among patients with survival data, 9.5% (n=4) experienced a relapse in a different organ (e.g., pelvic bone and lungs) following curative surgery. Three of these patients (75.0%) had PIK3CA mutations, with two harboring the H1047R mutation (50%) and one carrying the E542K mutation (25%).

<sup>▲:</sup> association is significant at 5% level, OR 4.293, 95% CI 1.279-14.408

The presence of a PIK3CA mutation was thereby significantly associated with reduced RFS (p<0.001), as shown in the Kaplan-Meier curve (Fig 2A and Table 3). Patients with a *PIK3CA* mutation had 26.19 times higher odds of relapse compared to the those without a mutation (HR 26.19, 95% CI 2.67-256.47). The mean RFS for patients with *PIK3CA* mutations was 26.5 months.

Fig 2. Kaplan-Meier survival estimates for relapse-free survival (RFS) stratified by PIK3CA mutation status (A), status of lymph node (LN) metastasis (B) and Ki67 proliferative status (C) while (D) shows the multivariate impact of all above three factors – PIK3CA mutation, LN metastasis and Ki67 index on RFS.

261 Fig. 2A: p-value<0.001, HR 26.187, 95% CI 2.674 – 256.475

Fig. 2B: p-value=0.026, HR 123.939, 95% CI could not be generated with statistical robustness due to

263 small sample size

252

253

254

255

256

257

258

259

260

262

265

266

267

269

264 Fig. 2C: p-value=0.029, HR 79.688, 95% CI could not be generated with statistical robustness due to

small sample size

Fig.2D: p-value=0.00048, HR and 95% CI could not be generated with statistical robustness due to

small sample size

268 HR: hazard ratio, CI: confidence interval

# Table 0. Impact of the overall and specific PIK3CA mutation status on relapse-free

### 270 survival (RFS)

	p-value	Hazard Ratio Exp (B)	95% CI
Association between <i>PIK3CA</i> mutation & RFS	**<0.001	26.187	2.674 – 256.475
	PIK3CA mutated	PIK3CA not mutated	
Mean RFS (months)	26.5	54.5	
95% CI of mean	13.99 - 39.01	51.12 - 57.84	

Table 3 continued

Median RFS in	37.00		_		
months (95% CI)	(0.00-81.91)				
PIK3CA Mutation	Relapse	No relapse	Total	p-value	
	(n)	(n)	(n)	<del>-</del>	
H1047D	2	2	1		

(n) (n) (n)	$(\mathbf{n})$ $(\mathbf{n})$
H1047R 2 2 4	2 4
Other 1 1 2	1 2
Total 3 3 6 0.281	3 6 0.281

<sup>\*\*:</sup> Association is significant at 1% level

272

273

274

275

276

277

278

279

280

281

282

283

284

However, no significant association was found between individual PIK3CA hotspot mutations (H1047R or E542K) and RFS (Table 3).

# Impact of selected clinicopathological features on RFS

LN metastasis was significantly associated with RFS (Table 4). Patients with LN-positive status had 123.94 times higher hazard of relapse compared to LN-negative patients (p=0.026, HR 123.94; Fig 2B). Additionally, a significant association was observed between Ki67 proliferative status and RFS, with patients having higher proliferative indices facing a 79.69 times higher hazard of relapse compared to those with Ki67 indices <20% (p=0.029, HR 79.69; Fig 2C).

Table 4. Univariate analysis of relapse-free survival (RFS) with selected clinicopathological parameters

Parameter	Relapse	No relapse	Total	p-value
	(n)	(n)		
All	4	38	42	
Age at diagnosis				
≤50 years	1	10	11	
>50 years	3	28	31	0.772
Histological type				
IBC-NST	3	31	34	
Others	1	7	8	0.701
Tumor grade/				
differentiation				
G1/ well-differentiated	1	13	14	

CI: confidence interval, RFS: Relapse-free survival

<sup>&</sup>quot;Other" includes the E542K mutation and the H1047R/E542K co-mutation

perpetuity.

It is made available under a CC-BY 4.0 International license.

			•
Tab	le 4	continue	1

285

286

287

	1 abic 4 continued		
3	23	26	0.717
1	9	10	
2	21	23	0.941
3.164			0.830
,			
3	26	29	
0	3	3	0.585
0	19	19	
-			*0.026
	12	10	V:V=V
4	37	41	
	1	1	0.769
	<u>-</u>	<del>-</del>	0.,00
3	30	33	
1	8	9	0.805
	<u> </u>	-	
4	37	41	
0	1	1	0.769
0	3	3	
4	34	38	0.529
4	33	37	
0	5	5	0.417
0	19	19	
4	15	19	<b>▲</b> 0.029
4	33	37	
0	4	4	0.478
	1 2 3.164 3 0 0 3 1 4 0 0 4 0 4 0	3 23  1 9 2 21 3.164  3 26 0 3  0 19 3 12  4 37 0 1  3 30 1 8  4 37 0 1  0 3 4 34  4 33 0 5  0 19 4 15	1     9     10       2     21     23       3.164     26     29       0     3     3       0     19     19       3     12     15       4     37     41       0     1     1       3     30     33       1     8     9       4     37     41       0     1     1       0     3     3       4     34     38       4     33     37       0     5     5       0     19     19       4     15     19       4     15     19

<sup>\*:</sup> association is significant at 5% level, HR 123.929, A statistically robust 95% CI not generated due to small sample number

immunohistochemical, LN: Lymph Node, PR: progesterone receptor, pT: pathological tumor stage, SHR: steroid hormone receptor, TNBC: triple-negative breast cancer

No other clinicopathological characteristics showed significant associations with RFS.

**<sup>△:</sup> association is significant at 5% level, HR 79.688,** A statistically robust 95% CI not generated due to small sample number

CI: confidence interval, ER: estrogen receptor, HER2: human epidermal growth factor receptor 2, HR: hazard ratio, IBC-NST: invasive breast carcinoma of no special type, IHC:

Finally, the multivariate Cox proportional hazard model (Fig 2D) demonstrated a significant association between the presence of a *PIK3CA* mutation, LN metastasis and a high Ki67 index with RFS (p<0.001).

# **Discussion**

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

309

310

311

This study, to our knowledge, is the first to profile *PIK3CA* mutations, assess their prognostic value, and evaluate the implications of patient ancestry on somatic mutations in Sri Lankan breast cancer patients. Despite being a pilot study conducted in an underrepresented island population, our findings lay the groundwork for future research, including meta-analyses in larger cohorts. The analysis of the clinicopathological parameters showed a median age of 58 years at breast cancer diagnosis, higher than the median age reported in a Sri Lankan study done over a decade ago, and higher than those reported from several Southeast Asian countries and Arab countries [26-29]. This could be due to Sri Lanka having one of the fastest ageing populations in the world [26]. The exponentially growing population of older women [26] would thus raise the incidence of breast cancer among this demographic, making it a key factor in the observed age shift in diagnosis. However, the fact that the majority of patients were already at stage 2 at the time of diagnosis, even with slow-growing cancers (i.e., luminal A and B), suggests a much earlier onset of the disease. This trend, consistent with other Asian countries, could probably be attributed to similar genetic and sociocultural factors and contrasts with developed Western countries, where median age of diagnosis occurs much later [30]. Similar to reports by previous studies conducted in Sri Lanka [31,32], it is noticeable that a majority of the tumors in our cohort were invasive breast carcinomas (IBC-NST) of tumor

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

grade 2 and/or stage II at diagnosis. This could be likely due to the absence of an established screening program aimed at early detection in Sri Lanka, thus reducing the likelihood of the cancer being detected at stage I and worsening disease outcomes [31]. These observations therefore highlight the need for the implementation of an effective screening system for breast cancer in Sri Lanka, to facilitate early diagnosis and ultimately reduce the overall burden of breast cancer in the country. Consistent with both local and global statistics [31-33], most tumors were ER/PR+ and HER2-, confirming that SHR+/HER2- luminal subtypes are the most common in Sri Lanka. One of the study's primary objectives was to catalog *PIK3CA* mutations in the cohort of patients and to detect associations with clinicopathological features. The detection of H1047R and E542K mutations in 17.46% of cases falls within the prevalence range of *PIK3CA* mutations reported in many global studies on breast cancer [5-10]. Notably, this study also provides the first evidence of PIK3CA mutations in Sri Lankan breast cancer patients. India, the closest nation to Sri Lanka both geographically and genetically, reports a *PIK3CA* mutation prevalence of 23.2% [34], closely aligned with our findings. This similarity likely reflects common hereditary factors shaped by historical migrations and cultural exchanges, which may have influenced the prevalence of *PIK3CA* mutations in the South Asian region. Although the predominance of H1047R as the most frequently observed *PIK3CA* mutation mirrors observations in other populations [35], our study reports a much a higher frequency of 81.81% for H1047R among the total *PIK3CA* mutations, compared to the frequency ( $\approx$ 58%) reported in other studies [35,36]. A particularly rare and unexpected observation was the absence of the E545K mutation in our cohort, which is commonly reported as a moderately prevalent PIK3CA mutation (≈10%) in many other global populations [37,38]. This observation aligns with findings from an Iranian study, where the E545K mutation was perpetuity.

It is made available under a CC-BY 4.0 International license .

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

similarly absent [39]. Given that over 96% of our cohort comprises Sri Lankan Sinhalese and Sri Lankan Burghers (both of Indo-Aryan ancestry), this shared absence is likely to be stemming from a common ancestral link with Iranians, as both Iranians and Indo-Aryans are descendants of the Indo-Iranian branch of the Indo-European language family [23,24,40]. The absence of the E545K mutation, may thus be tied to ancestral roots, and consequent genetic backgrounds, among other possible factors. This provides valuable preliminary data from Sri Lanka, contributing to the global effort of cataloging *PIK3CA* mutations, which are highly heterogeneous across populations with different ancestral origins [10]. The significant association between patient ancestry and the presence of a PIK3CA mutation (p=0.028), where the Indo-Aryan and Dravidian ancestries could potentially be associated with differing rates of PIK3CA mutations, suggests that ancestral influence tied to ethnic backgrounds could affect the occurrence of *PIK3CA* mutations in Sri Lanka as well as in South Asia. Though the strength of this observation is hampered by the small sample size, particularly with respect to the patients of Dravidian origin (one Tamil and one Moor in the entire cohort), the presence of *PIK3CA* mutations in both of them cannot be disregarded and warrant further ancestry-oriented mutational analyses. While this association aligns with global findings that somatic PIK3CA mutations are linked with ancestry across all cancer types including breast cancer [19-22], our study fills an important gap by investigating these ancestry-specific associations in a cohort, exclusively of South Asian ancestry. These insights may have significant implications for personalized treatment strategies, which may need to be tailored based on the patient's ancestry, as mutation profiles observed in one ancestry may not apply to others – in turn influencing treatment efficacy and outcomes. Another notable observation was that the *PIK3CA* mutations in the cohort were exclusively seen in SHR+/HER2- luminal tumors, consistent with a similar subtype-specific dominance of

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380

381

382

383

384

the mutation in previous studies [9]. The molecular mechanisms, including cross talk between the PI3K/AKT/mTOR and ER signaling pathways are postulated to be mediating this, with PIK3CA mutations driving oncogenesis via ER signaling, thereby predominating in SHR+ breast cancer subtypes [17]. The significant association between PIK3CA mutations and increased likelihood of axillary LN metastasis (p=0.036, OR 9.60) highlights the potential prognostic value of *PIK3CA* mutations in predicting breast cancer progression in the Sri Lankan context. LN metastasis typically indicates a more advanced disease stage, a higher risk of distant metastases and worse outcomes [41]. Therefore, PIK3CA mutation testing could guide therapeutic strategies. particularly in decisions related to axillary management and risk assessment, with more intensive therapeutic approaches needed by patients with tumor-positive axillary LNs [42]. Divergent findings in other studies [43], may reflect differences in genetic makeup and lifestyle factors, further emphasizing the need for nuanced molecular investigations in underrepresented populations like Sri Lanka. The absence of associations between clinicopathological features and age group may indicate that other parameters, such as histological grade and Ki67 index, hold greater prognostic value than age, particularly in early-stage breast cancer cohorts [44], like ours. This is supported by the significant association between higher Ki67 indices and an increased risk of developing higher-grade tumors (p=0.024, OR 4.29). These findings further support the use of Ki67 index as a valuable prognostic marker [45] in Sri Lankan breast cancer patients and its importance in clinical decision-making. The striking association between PIK3CA mutations and reduced RFS in Sri Lankan breast cancer patients, with high statistical significance (p<0.001, HR 26.19, 95% CI 2.67 – 256.47) suggests that these mutations have a considerable impact on disease prognosis. The broad

386

387

388

389

390

391

392

393

394

395

396

397

398

399

400

401

402

403

404

405

406

407

408

confidence interval reflects the small sample size, but even the lower bound presents a significantly increased risk of relapse, nearly three times greater than patients without a PIK3CA mutation. This implies a significant impact of PIK3CA mutations on disease progression and brings out its potential clinical relevance as a prognostic biomarker in Sri Lankan breast cancer patients. As the first study to analyze *PIK3CA* mutations in Sri Lankan breast cancer patients, our findings are consistent with results from other Asian studies as well as studies on other malignancies, such as colorectal cancer [13,46,47]. However, our results did not show mutation-specific associations with RFS, which may be attributed to the smaller cohort size, necessitating further investigation with larger studies. Nevertheless, the predominance of the H1047R mutation- with an observed frequency of 0.81 within the total mutations, suggests that it is likely to be responsible for reducing RFS [35] in our cohort, mirroring findings of the aforementioned Iranian study [39]. Given the shared Indo-Iranian ancestry of the Sinhalese and Iranians, this parallel may hint at ancestral genetic traits influencing both mutation occurrence and its clinical impact. This further emphasizes the need for nuanced investigations and personalized treatment approaches in populations with specific ancestral backgrounds. Our analysis of clinicopathological characteristics also revealed that LN metastasis and Ki67 proliferative index are key determinants of relapse risk. Patients with either tumor-positive LNs or a higher Ki67 index ( $\geq 20\%$ ), exhibited a significantly greater hazard of relapse compared to their counterparts without tumor deposits in LNs (p=0.026, HR 123.93) and with lower proliferative indices (p=0.029, HR 79.68). These results reinforce the established role of LN metastasis and cellular proliferation rates as reliable indicators of relapse and survival in breast cancer patients [48-50], while also suggesting underlying molecular mechanisms that contribute to cancer recurrence [50]. This further underscores the importance of these factors in staging, prognosis, and therapy of invasive breast cancer in Sri Lankan patients.

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

One of the most paramount points in our study is the validation of the observed association between LN metastasis and RFS (p=0.026) by the compounded association of PIK3CA mutations with both LN metastasis (p=0.036) and significantly reduced RFS (p<0.001). This enables us to bridge all three findings. Additionally, the multivariate model demonstrated the compounded impact of all these factors (p<0.001) on the likelihood of disease relapse, ultimately emphasizing the importance of considering all three factors- PIK3CA mutations, LN status, and Ki67 index- along with patient ancestry, in prognosis and treatment planning for breast cancer patients in Sri Lanka and across South Asia. This may also suggest an underlying mechanistic link that contributes to the aggressive behavior of breast cancer. It is plausible that in ancestries more prone to the occurrence of PIK3CA mutations in malignant cells, these mutations promote the cancer spread via lymphatic channels, leading to LN metastasis and subsequent recurrence. This progression highlights a crucial step in cancer spread, as LNs function as critical filtering sites within the lymphatic system, where cancer cells infiltrate and establish secondary tumor deposits [52]. The above findings align with Stephen Paget's 'Seed and soil hypothesis,' which proposes that metastasis occurs when certain tumor cells (the "seed") preferentially grow in particular organ microenvironments (the "soil") - and that metastases only develop when the right seed is implanted in the right soil [53]. Our study suggests that PIK3CA driver mutations, possibly the predominant H1047R mutation, may act as a genetic change that enhances the metastatic potential of breast cancer cells by promoting survival and proliferation. These genetic alterations could facilitate the invasion of lymphatic vessels, leading to the establishment of metastatic colonies in LNs. In this context, *PIK3CA* mutations may assist in planting the "seed"

435

436

437

438

439

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

in the "soil" by promoting the establishment of tumor deposits in axillary LNs. Strikingly, further developments to this hypothesis, elaborate how the above mechanisms could result in the primary breast cancer metastasizing to the lungs and bones [54], the exact two organs of relapse diagnosed in our PIK3CA-mutated patient population. Therefore, by elucidating this molecular pathway, our study offers valuable insights into the potential role of PIK3CA in the underlying biology of aggressive breast cancers, particularly in the Sri Lankan population. To our knowledge, PI3K inhibitors are not currently prescribed for breast cancer patients in Sri Lanka. Our study's preliminary observation of a negative prognostic outcome in the predominantly SHR+/HER2-, Sri Lankan breast cancer cohort with *PIK3CA* mutations, serves as a calling out for Sri Lankan clinicians to incorporate PIK3CA mutational testing in routine diagnostic protocols. Patients identified with these mutations could benefit from PI3Ka inhibitors such as Alpelisib, which are approved for this clinical scenario and are known to prolong the RFS in patients [55]. Furthermore, this treatment approach could be tailored for high risk ethnic groups within Sri Lanka (i.e. those with Dravidian ancestry), should a larger study with a better representation of ethnic minority groups, confirm the association of PIK3CA mutations with patient ancestry. This personalized approach could extend beyond breast cancer to other malignancies such as colorectal, gastric, ovarian, and cervical cancers, which have also exhibited *PIK3CA* mutations and consequent impacts on prognosis [8,56]. Despite the significant implications of our study, there are several limitations. The primary limitation is the sample size, which was restricted due to financial and logistical constraints.

Despite the significant implications of our study, there are several limitations. The primary limitation is the sample size, which was restricted due to financial and logistical constraints. This limitation impacted the statistical power of several results and affected the ability to perform robust regression and multivariate analyses. Additionally, the retrospective nature of our study also introduced certain constrains. For example, the grouping of patients into broad

460

461

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

ancestral categories was based on self-reported ethnicity in hospital records of the patients, rather than genetic testing. Although studies indicate a high concordance between self-reported ancestry and genetic testing results [22], potential misclassification may have oversimplified the complex genetic landscape of the Sri Lankan population. Furthermore, the underrepresentation of minority ethnic groups due to the uneven geographical distribution of these populations, greatly impaired the power of the detected association of ancestry with mutation status. Overcoming this limitation might require recruiting patients from a broader array of hospitals and oncology clinics around the country, to ensure adequate representation of all ancestral groups. Another limitation is the absence of data on other potentially interacting mutations within the PIK3CA gene or in other OGs and TSGs that were not tested in the cohort, and their interplay with the tested mutations. Additionally, the follow-up period in our study was relatively short. All patients with survival data (n=42) were alive, and 90.5% remained recurrence-free within 5 years post-diagnosis, which limited the survival analysis to RFS as a proxy. A longer followup period would provide a more comprehensive understanding of long-term outcomes. Nevertheless, this pilot study, the first to analyze *PIK3CA* mutations in relation to breast cancer in different ancestries in Sri Lanka, together with its observed prognostic implications, offers sufficient insight and direction to the chosen objectives, so that a larger, more conclusive study can be conducted to confirm and validate the reported findings. Accordingly, a study on a larger Sri Lankan cohort with a subsequent functional analysis is necessary to address the above limitations, especially to confirm the absence of the E545K mutation in Sri Lankan breast cancer patients and to validate the significance of observed mutations, particularly in the Dravidian population, which appears to be at higher risk based on our findings.

## **Conclusion**

This study is the first to report on *PIK3CA* mutations in Sri Lankan breast cancer patients, a population with a unique genetic heritage, demonstrating a *PIK3CA* mutation prevalence of 17.46% and significant associations between ancestry-linked mutations, LN metastasis and cancer relapse. Our findings also suggest the existence of a possible molecular link contributing to metastasis.

Notably, our observation of a significant association between patient ancestry and *PIK3CA* mutation status is the first of its kind in an exclusively South Asian cohort. This invites comparisons with similar findings - such as the absence of the E545K mutation - in global populations with shared ancestries. Our findings also provide a foundation for prognostic stratification and therapeutic decision-making for breast cancer patients in Sri Lanka - rooted in the presence of *PIK3CA* mutations and patient ancestry - for identifying high-risk patient subsets who may benefit from targeted therapies such as PI3K inhibitors, which are not currently prescribed in Sri Lanka. Further large-scale functional studies are necessary to validate these findings and to improve clinical outcomes for breast cancer patients in Sri Lanka.

# **Acknowledgements:**

We gratefully acknowledge the invaluable support provided by the staff at the Centre for Immunology and Molecular Biology (CIMB) and the Centre for Transgenic Technologies at the Faculty of Science, University of Colombo, Sri Lanka, as well as the medical laboratory technicians at the Diagnostics Laboratory of University Hospital KDU, Sri Lanka in the completion of the laboratory component of this research.

# **References:**

504

505

506

507

508

509

510

511

512

513

514

515

516

517

518

519

520

521

522

523

524

525

526

527

1. Barakeh DH, Aljelaify R, Bashawri Y, Almutairi A, Algubaishi F, Alnamnakani M, et al. Landscape of somatic mutations in breast cancer: new opportunities for targeted therapies in Saudi Arabian patients. Oncotarget [Internet]. 2021 Mar 30 [cited 2022] Mar 24];12(7):686–97. Available from: https://www.oncotarget.com/article/27909/text/ 2. Fan L, Goss PE, Strasser-Weippl K. Current Status and Future Projections of Breast Cancer in Asia. Breast Care. 2015;10(6):372–8. 3. Zhukova LG, Andreeva II, Zavalishina LE, Zakiriakhodzhaev AD, Koroleva IA, Nazarenko AV, et al. Breast cancer. Современная онкология [Internet]. 2021 May 1 [cited 2023 Jan 16];23(1):5–40. Available from: https://doaj.org/article/30b4e9318d3543faa6dfbfe39ff5c88d 4. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009 Apr;458(7239):719-24. 5. Miricescu D, Totan A, Stanescu-Spinu II, Badoiu SC, Stefani C, Greabu M. PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects. International Journal of Molecular Sciences. 2020 Dec 26;22(1):173. 6. Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, et al. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology & Therapy. 2004 Aug;3(8):772–5. 7. Samuels Y, Waldman T. Oncogenic Mutations of PIK3CA in Human Cancers. Current Topics in Microbiology and Immunology [Internet]. 2010 [cited 2019 Oct 8];21–41. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3164550/

529

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

8. Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers. British Journal of Cancer [Internet]. 2006 Jan 31 [cited 2019 Oct 8];94(4):455–9. Available from: https://www.nature.com/articles/6602970 9. Reinhardt K, K Stückrath, Hartung C, Kaufhold S, Christoph Uleer, Hanf V, et al. PIK3CA-mutations in breast cancer. Breast cancer research and treatment [Internet]. 2022 Oct 24;196(3):483–93. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9633529/ 10. Chen JW, Murugesan K, Newberg JY, Sokol ES, Savage HM, Stout TJ, et al. Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. JCO Precision Oncology. 2022 Nov;(6). 11. Li SY, Rong M, Grieu F, Iacopetta B. PIK3CA mutations in breast cancer are associated with poor outcome. Breast Cancer Research and Treatment. 2005 Nov 30;96(1):91–5. 12. Hu H, Zhu J, Zhong Y, Geng R, Ji Y, Guan Q, et al. PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K/AKT/mTOR signaling pathway. Annals of Translational Medicine [Internet]. 2021 Mar 1 [cited 2021 Dec 21];9(5):410–0. Available from: https://atm.amegroups.com/article/view/64371/html 13. Cho YA, Ko SY, Suh YJ, Kim S, Park JH, Park HR, et al. PIK3CA Mutation as Potential Poor Prognostic Marker in Asian Female Breast Cancer Patients Who Received Adjuvant Chemotherapy. Current Oncology. 2022 Apr 19;29(5):2895–908. 14. Fillbrunn M, Signorovitch J, André F, Wang I, Lorenzo I, Ridolfi A, et al. PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials. BMC Cancer. 2022 Sep 21;22(1).

553

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569

570

571

572

573

574

575

15. Zagami P, Aranzazu Fernandez-Martinez, Rashid NU, Hoadley KA, Spears PA, Curigliano G. et al. Association of PIK3CA Mutation With Pathologic Complete Response and Outcome by Hormone Receptor Status and Intrinsic Subtype in Early-Stage ERBB2/HER2-Positive Breast Cancer. JAMA Network Open. 2023 Dec 20;6(12):e2348814-4. 16. Cizkova M, Susini A, Vacher S, Cizeron-Clairac G, Andrieu C, Driouch K, et al. PIK3CA mutation impact on survival in breast cancer patients and in ERα, PR and ERBB2-based subgroups. Breast Cancer Research: BCR [Internet]. 2012;14(1):R28. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3496146/ 17. Zardavas D, te Marvelde L, Milne RL, Fumagalli D, Fountzilas G, Kotoula V, et al. Tumor PIK3CA Genotype and Prognosis in Early-Stage Breast Cancer: A Pooled Analysis of Individual Patient Data. Journal of Clinical Oncology. 2018 Apr 1;36(10):981–90. 18. Wang S, Pitt JJ, Zheng Y, Yoshimatsu TF, Gao G, Sanni A, et al. Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria. International Journal of Cancer. 2019 Jun 7;145(12):3321–33. 19. Pitt JJ, Riester M, Zheng Y, Yoshimatsu TF, Sanni A, Oluwasola O, et al. Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features. Nature Communications [Internet]. 2018 Oct 16 [cited 2021 Sep 22];9(1):4181. Available from: https://www.nature.com/articles/s41467-018-06616-0#Sec10 20. Keenan T, Moy B, Mroz EA, Ross K, Niemierko A, Rocco JW, et al. Comparison of the Genomic Landscape Between Primary Breast Cancer in African American Versus

577

578

579

580

581

582

583

584

585

586

587

588

589

590

591

592

593

594

595

596

597

598

599

White Women and the Association of Racial Differences With Tumor Recurrence. Journal of Clinical Oncology. 2015 Nov 1;33(31):3621–7. 21. Carrot-Zhang J, Chambwe N, Damrauer JS, Knijnenburg TA, Robertson AG, Yau C, et al. Comprehensive analysis of genetic ancestry and its molecular correlates in cancer. Cancer Cell. 2020 May;37(5). doi:10.1016/j.ccell.2020.04.012 22. Arora K, Tran TN, Kemel Y, Miika Mehine, Liu YL, Subhiksha Nandakumar, et al. Genetic Ancestry Correlates with Somatic Differences in a Real-World Clinical Cancer Sequencing Cohort. Cancer Discovery. 2022 Sep 1;12(11):2552–65. 23. Perera N, Galhena G, Ranawaka G. X-chromosomal STR based genetic polymorphisms and demographic history of Sri Lankan ethnicities and their relationship with global populations. Scientific Reports. 2021 Jun 17;11(1). 24. Singh PP., Kumar S, Pasupuleti N, Weerasooriya PR, van Driem G, Tennekoon KH, et al. Reconstructing the population history of Sinhalese, the major ethnic group in Śrī Lańkā. iScience [Internet]. 2023 Oct 1;26(10):107797–7. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10514440/ 25. Vithana PVSC, Dheerasinghe DSAF, Handagiripathira HMI, Alahapperuma S, Nilaweera I, Perera S. Sri Lankan Patterns of Female Cancers: Incidence and Mortality Over 1995-2010. Asian Pacific Journal of Cancer Care. 2021 Mar 26;6(1):27–33. 26. Fernando A, Jayarajah U, Prabashani S, Fernando EA, Seneviratne SA. Incidence trends and patterns of breast cancer in Sri Lanka: an analysis of the national cancer database. BMC Cancer. 2018 Apr 27;18(1). 27. Anwar SL, Raharjo CA, Herviastuti R, Dwianingsih EK, Setyoheriyanto D, Avanti WS, et al. Pathological profiles and clinical management challenges of breast cancer

601

602

603

604

605

606

607

608

609

610

611

612

613

614

615

616

617

618

619

620

621

622

623

emerging in young women in Indonesia: a hospital-based study. BMC Women's Health. 2019 Feb 6;19(1). 28. Najjar H, Easson A. Age at diagnosis of breast cancer in Arab nations. International Journal of Surgery. 2010;8(6):448–52. doi:10.1016/j.ijsu.2010.05.012 29. Abdel-Razeq H, Almasri H, Abdel Rahman F, Abdulelah H, Abu Nasser M, Salam M, et al. Clinicopathological Characteristics And Treatment Outcomes Of Breast Cancer Among Adolescents And Young Adults In A Developing Country. Cancer Management and Research. 2019 Nov 1; Volume 11:9891–7. 30. Leong SPL, Shen ZZ, Liu TJ, Agarwal G, Tajima T, Paik NS, et al. Is Breast Cancer the Same Disease in Asian and Western Countries? World Journal of Surgery [Internet]. 2010 [cited 2021 May 28];34(10):2308–24. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2936680/ 31. Balawardena J, Skandarajah T, Rathnayake W, Joseph N. Breast Cancer Survival in Sri Lanka. JCO Global Oncology. 2020 Apr;(6):589–99. 32. Perera R, Senanayake A, Balawardana J, Malviarachchi S, Kumarasinghe I, De Silva A. Clinicopathological analysis of breast cancers in a single unit of a Sri Lankan tertiary care hospital. Sri Lanka Journal of Cancer [Internet]. 2023;3(1):27–35. Available from: https://slco.lk/wp-content/uploads/2023/09/j5.pdf 33. Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LAG, et al. US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 Status. JNCI: Journal of the National Cancer Institute [Internet]. 2014 Apr 28;106(5). Available from: <a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580552/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4580552/</a> 34. Ahmad F, Badwe A, Verma G, Bhatia S, Das BR. Molecular evaluation of PIK3CA gene mutation in breast cancer: determination of frequency, distribution pattern and

625

626

627

628

629

630

631

632

633

634

635

636

637

638

639

640

641

642

643

644

645

646

647

648

its association with clinicopathological findings in Indian patients. Medical Oncology. 2016 Jun 9;33(7). 35. Mangone F, Bobrovnitchaia I, Salaorni S, Manuli E, Nagai M. PIK3CA exon 20 mutations are associated with poor prognosis in breast cancer patients. Clinics. 2012 Nov 7;67(11):1285–90. 36. Lai YL, Mau BL, Cheng WH, Chen HM, Chiu HH, Tzen CY. PIK3CA exon 20 mutation is independently associated with a poor prognosis in breast cancer patients. Annals of Surgical Oncology [Internet]. 2008 Apr 1 [cited 2020 Nov 24];15(4):1064-9. Available from: https://pubmed.ncbi.nlm.nih.gov/18183466/ 37. Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, et al. Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Research. 2020 May 13;22(1). 38. Chao T, Tsai Y, Liu C, Lien PJ, Lin Y, Feng CJ, et al. Prevalence of PIK3CA mutations in Taiwanese patients with breast cancer: a retrospective next-generation sequencing database analysis. Frontiers in Oncology [Internet], 2023 Aug 15 [cited 2024 Jan 24];13. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10466395/ 39. Nazeri E, Parniani M, Olfatbakhsh A, Najafi S, Peyman M, Karami B, et al. Evaluation of PIK3CA Gene Mutations in Breast Cancer Patients Treated by Trastuzumab. Archives of Breast Cancer. 2023 Jun 16;248–55. 40. Indo-Iranian languages [Internet]. Encyclopedia Britannica. Available from: https://www.britannica.com/topic/Indo-Iranian-languages 41. Luo M, Lin X, Hao D, Kangle Wang Shen, Wu W, Wang L, et al. Incidence and risk factors of lymph node metastasis in breast cancer patients without preoperative chemoradiotherapy and neoadjuvant therapy: analysis of SEER data. Gland Surgery

650

651

652

653

654

655

656

657

658

659

660

661

662

663

664

665

666

667

668

669

670

671

672

[Internet]. 2023 Nov 1 [cited 2024 Aug 27];12(11):1508–24. Available from: https://pubmed.ncbi.nlm.nih.gov/38107495/ 42. Rao R. The Evolution of Axillary Staging in Breast Cancer. PubMed. 2015 Nov 27:112(5):385-8. 43. Kalinsky K, Jacks LM, Heguy A, Patil S, Drobnjak M, Bhanot UK, et al. PIK3CA Mutation Associates with Improved Outcome in Breast Cancer. Clinical Cancer Research. 2009 Aug 11;15(16):5049–59. 44. Arikan AE, Kara H, Dülgeroğlu O, Erdoğan EN, Capkinoglu E, Uras C. Do prognosis and clinicopathological features differ in young early-stage breast cancer? Frontiers in Surgery [Internet]. 2022 Oct 19 [cited 2024 Sep 29];9. Available from: https://doi.org/10.3389/fsurg.2022.900363 45. Kanyılmaz G, Yavuz BB, Aktan A, Karaağaç M, Uyar M, Fındık S. Prognostic Importance of Ki-67 in Breast Cancer and Its Relationship with Other Prognostic Factors - European Journal of Breast Health [Internet], Doi.org, 2019 [cited 2024 Sep 29]. Available from: https://doi.org/10.5152/ejbh.2019.4778 46. Deng L, Zhu X, Sun Y, Wang J, Zhong X, Li J, et al. Prevalence and Prognostic Role of PIK3CA/AKT1 Mutations in Chinese Breast Cancer Patients. Cancer Research and Treatment. 2019 Jan 15;51(1):128-40. 47. Kato S, Iida S, Higuchi T, Ishikawa T, Takagi Y, Yasuno M, et al. PIK3CA mutation is predictive of poor survival in patients with colorectal cancer. International Journal of Cancer. 2007;121(8):1771-8. 48. Rakha EA, Tan PH, Varga Z, Tse GM, Shaaban AM, Climent F, et al. Prognostic factors in metaplastic carcinoma of the breast: a multi-institutional study. British Journal of Cancer. 2014 Nov 25;112(2):283-9.

674

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

49. Sun X, Kaufman PD. Ki-67: more than a proliferation marker. Chromosoma [Internet]. 2018 Jun 1;127(2):175–86. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5945335/ 50. Liu N, Yang Z, Liu X, Niu Y. Lymph node status in different molecular subtype of breast cancer: triple negative tumours are more likely lymph node negative. Oncotarget. 2017 Feb 2;8(33). 51. Hao Y, Baker D, ten Dijke P. TGF-β-Mediated Epithelial-Mesenchymal Transition and Cancer Metastasis. International Journal of Molecular Sciences [Internet]. 2019 Jun 5;20(11):2767. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6600375/ 52. Ji H, Hu C, Yang X, Liu Y, Ji G, Ge S, et al. Lymph node metastasis in cancer progression: molecular mechanisms, clinical significance and therapeutic interventions. Signal Transduction and Targeted Therapy [Internet]. 2023 Sep 27 [cited 2023 Sep 29];8(1):1–33. Available from: https://www.nature.com/articles/s41392-023-01576-4 53. Paget S. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. The Lancet. 1889 Mar; 133(3421):571-3. 54. Langley RR, Fidler IJ. The seed and soil hypothesis revisited-The role of tumorstroma interactions in metastasis to different organs. International Journal of Cancer. 2011 Mar 25;128(11):2527–35. 55. André F, Ciruelos E, Rubovszky G, Campone M, Loibl S, Rugo HS, et al. Alpelisib for PIK3CA-Mutated, Hormone Receptor-Positive Advanced Breast Cancer. New England Journal of Medicine. 2019 May 16;380(20):1929–40.

697

698

699

700

701

702

703

704

705

706

707

56. Ogino S, Nosho K, Kirkner GJ, Shima K, Irahara N, Kure S, et al. PIK3CA Mutation Is Associated With Poor Prognosis Among Patients With Curatively Resected Colon Cancer. Journal of Clinical Oncology. 2009 Mar 20;27(9):1477–84. **Supporting Information** S1 Fig. Ethical approval for the study granted by the Ethics Review Committee of the Institute of Biology, Sri Lanka (ERC IOBSL 303 07 2023) S2 Fig. Age distribution of the cohort S3 Fig. Distribution of tumor size (cm) in the cohort S1 Table. Grouping of the variables used for the data analysis S2 Table. Status of lymph node (LN) metastasis and patient age group in selected clinical and histopathological groups




Figure 1




Figure 2 (A, B, C and D)




Figure 2A




Figure 2B




Figure 2C




Figure 2D